Netrin-1 (NTN1), a secreted laminin-related protein, plays critical roles in axon guidance, cell migration, and tissue morphogenesis during embryonic development. It acts as a chemoattractant or repellent by binding to receptors like DCC (Deleted in Colorectal Cancer) and UNC5 family members, regulating neural circuit formation. Beyond neurodevelopment, NTN1 is implicated in cancer progression, inflammation, and vascular biology, where it promotes tumor angiogenesis, metastasis, and immune evasion by modulating cell survival and adhesion pathways. NTN1 antibodies are essential tools for studying these mechanisms. They enable detection of NTN1 expression in tissues (via immunohistochemistry) or biological fluids (via ELISA), and functional blocking experiments to dissect its interactions with receptors. In cancer research, NTN1-targeting antibodies are explored as potential therapeutics to inhibit pro-tumorigenic signaling. Challenges include understanding context-dependent NTN1 functions and optimizing antibody specificity for clinical translation. Ongoing studies also investigate NTN1's role in neurodegenerative diseases and tissue repair, highlighting its broad therapeutic relevance.